Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed its Q3 2018 10-Q quarterly report on Nov 1, 2018 for the quarter ended Sep 30, 2018.
Teva Pharmaceutical Industries Ltd Q3 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $4,529M, down 19% YoY from $5,593M, driven by COPAXONE competition and U.S. generics price erosion
- Gross margin 44.6% vs 47.2%; operating margin 0.4% vs 6.7%; net loss $208M vs $595M income
- North America weakest segment: revenue $2,265M, down 26%, profit $649M, down 43%; Europe margin 56.4% vs 52.2%
- Operating cash flow $421M vs $795M; cash and investments $1,948M vs $1,942M; debt fell to $29,489M
- Headwinds: FDA OAI classification at Davie plant and valsartan recall impact of $46M; 2018 non-GAAP tax-rate outlook 14%
Risk Factors
- No material changes to previously disclosed risk factors in the December 31, 2017 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teva Pharmaceutical Industries Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.